Nielsen, Lyngby
Anette Sams Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20120245083 | Derivatives of CGRP - Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments. | 09-27-2012 |
Carl Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20090284934 | DATA ACQUISITION MODULE AND SYSTEM - The present invention relates to units or modules for data acquisition that may either be used as stand alone units or be used to form a modular system where a plurality of modules are mounted together in a frame or rack structure as well as combinations of such stand-alone units and frames. More specifically the invention relates to a module for data acquisition comprising a detachable front unit ( | 11-19-2009 |
Claus Henrik Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20150376294 | ANTI-PAD2 ANTIBODIES AND TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to anti-peptidylarginine deiminase 2 (PAD2) antibodies and anti-PAD2 antibodies for use in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (RA). The invention further relates to a method for treatment of an autoimmune disease characterized by extracellular citrullination comprising the administration of a suitable amount of an anti-PAD2 antibody to a subject. | 12-31-2015 |
Hanne Philbert Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20160068788 | Liquid Automatic Dish Washing Detergent Compositions - The stabilization of subtilisins by peptide aldehydes, hydrosulfite adducts thereof or peptide methyl ketones, is particularly effective in liquid ADW detergents which contain a strong sequestering builder. | 03-10-2016 |
20160076012 | Detergent Compositions - The present invention relates to detergent compositions comprising a variant of a parent lipase which variant has lipase activity, has at least 60% but less than 100% sequence identity with SEQ ID NO: 2, and comprises substitutions at positions corresponding to T231R+N233R and at least one or more (e.g., several) of D96E, D111A, D254S, G163K, P256T, G91T, and G38A of SEQ ID NO: 2. The present invention also relates to use of the compositions, methods of producing the compositions, and methods of cleaning. The present invention furthermore relates to variants and polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides. | 03-17-2016 |
Hans Jorgen Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20080261246 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER - The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA. | 10-23-2008 |
20090035794 | METHOD FOR DETECTING, SCREENING, AND/OR MONITORING CANCER IN AN INDIVIDUAL - The invention relates to a method for screening and/or detecting and/or monitoring a cancer in an individual, said method comprising determining a first parameter represented by the concentration of TIMP-1 in at least one excreta, e.g. saliva, from the individual. The invention provides a method that without the need to use a blood sample is suitable for facilitating the early diagnosis of a cancer, monitoring the recurrence of a cancer, and/or monitoring the status of a cancer or the effect of cancer treatment in an individual. | 02-05-2009 |
Hans Jørgen Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20110060529 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER - The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. | 03-10-2011 |
20110294148 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER - The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA. | 12-01-2011 |
Henrik Bjorn Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20130039548 | Genome-Wide Association Study Identifying Determinants Of Facial Characteristics For Facial Image Generation - The present invention relates to a method for the generation of a facial composite from the genetic profile of a DNA-donor. The method comprises the steps of a) subjecting a biological sample to genotyping thereby generating a profile of genetic markers associated to numerical facial descriptors (NFD) for said sample, b) reverse engineer a NFD from the profile of the associated genetic variants and constructing a facial composite from the reverse engineered numerical facial descriptors (NFDs). The present invention also relates to a method for identifying genetic markers and/or combinations of genetic markers that are predictive of the facial characteristics, (predictive facial markers) of a person, said method comprising the steps of: a) capturing images of a group of individual faces; b) performing image analysis on facial images of said group of individual faces thereby extracting phenotypical descriptors of the faces; c) obtaining data on genetic variation from said group of individual and d) performing a genome-wide association study (GWAS) to identify said predictive facial markers. | 02-14-2013 |
Jan Frank Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20120143149 | Needle Mounting System and a Method for Mounting a Needle Assembly - A needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount. | 06-07-2012 |
20140025018 | NEEDLE MOUNTING SYSTEM AND A METHOD FOR MOUNTING A NEEDLE ASSEMBLY - A needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount. | 01-23-2014 |
Lone Kierstein Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20110212877 | DETERGENT COMPOSITION - Peptide aldehydes containing a ureido group are effective as stabilizers for protease in a detergent composition, and as stabilizers for a second enzyme in a liquid composition with a protease. | 09-01-2011 |
Martin Dybendal Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20090202204 | OPTICAL COUPLER, A METHOD OF ITS FABRICATION AND USE - The invention relates to: An optical coupler for coupling light from at least two input fibres into one output fibre. The invention further relates to a method of fabricating and to the use of an optical coupler. The object of the present invention is to provide an optical coupler, which is relatively easy to manufacture. The problem is solved in that the coupler comprises a) an input section comprising at least two input fibres, which are bundled over a bundling-length and having an output end face at one end of the bundling-length; and b) an output section comprising an output fibre comprising a confining region for confining light propagated in said input fibres and a surrounding cladding region and having an input end face; | 08-13-2009 |
Niels Fisker Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20100216864 | RNA Antagonist Compounds for the Modulation of PCSK9 - The present invention provides compounds, compositions and methods for modulating the expression of PCSK9. In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridisable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown to modulate the expression of PCSK9, and pharmaceutical preparations thereof and their use as treatment of hypercholesterolemia and related disorders are disclosed. | 08-26-2010 |
20110054011 | RNA Antagonist Compounds for the Modulation of FABP4/AP2 - Oligonucleotides directed against the FABP4 gene are developed for modulating the expression of FABP4 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding FABP4. Methods of using these compounds for modulation of FABP4 expression and for the treatment of diseases associated with over expression of FABP4 are provided. Examples of such diseases are the metabolic syndrome, diabetes, atherosclerosis, and inflammatory states such as arthritis. The oligomer may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid (LNA) or a combination thereof. | 03-03-2011 |
20120122954 | Antisense Oligomers Targeting PCSK9 - The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as hypercholesterolemia and related disorders. | 05-17-2012 |
Vibeke Friis Nielsen, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20160089381 | STABILITY OF PROGESTOGEN FORMULATIONS - In a preparation for hormone replacement therapy having a low content of progestogen, the stability of the progestogen component can be enhanced by using a cellulosic binder, for example hydroxypropylcellulose, in stead of a non-cellulosic binder. | 03-31-2016 |